Gabriele Müller

Gabriele Müller

Auto-generated profile, based on publicly available information

Gabriele Müller

Center for Evidence-Based Healthcare, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 September 2017 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
EWEleanor Wheeler
Eleanor Wheeler
ALAaron Leong
Aaron Leong
CLChing-Ti Liu
Ching-Ti Liu
MHMarie-France Hivert
Marie-France Hivert
RSRona Strawbridge
Rona Strawbridge
JMJames B. Meigs
James B. Meigs
Glycated hemoglobin (HbA1c) is used to diagnose type 2 diabetes (T2D) and assess glycemic control in patients with diabetes. Previous genome-wide association studies (GWAS) have identified 18 HbA1c-associated genetic variants. These variants proved to be classifiable by their likely biological action as erythrocytic (also associated with erythrocyte traits) or glycemic (associated with other glucose-related traits). In this study, we tested the hypotheses that, in a very large scale GWAS, we would identify more genetic variants associated with HbA1c and that HbA1c variants implicated in erythrocytic biology would affect the diagnostic accuracy of HbA1c. We therefore expanded the number of HbA1c-associated loci and tested the effect of genetic risk-scores comprised of erythrocytic or glycemic variants on incident diabetes prediction and on prevalent diabetes screening performance. Throughout this multiancestry study, we kept a focus on interancestry differences in HbA1c genetics performance that might influence race-ancestry differences in health outcomes. Using genome-wide association meta-analyses in up to 159,940 individuals from 82 cohorts of European, African, East Asian, and South Asian ancestry, we identified 60 common genetic variants associated with HbA1c. We classified variants as implicated in glycemic, erythrocytic, or unclassified biology and tested whether additive genetic scores of erythrocytic variants (GS-E) or glycemic variants (GS-G) were associated with higher T2D incidence in multiethnic longitudinal cohorts (N = 33,241). Nineteen glycemic and 22 erythrocytic variants were associated with HbA1c at genome-wide significance. GS-G was associated with higher T2D risk (incidence OR = 1.05, 95% CI 1.04–1.06, per HbA1c-raising allele, p = 3 × 10−29); whereas GS-E was not (OR = 1.00, 95% CI 0.99–1.01, p = 0.60). In Europeans and Asians, erythrocytic variants in aggregate had only modest effects on the diagnostic accuracy of HbA1c. Yet, in African Americans, the X-linked G6PD G202A variant (T-allele frequency 11%) was associated with an absolute decrease in HbA1c of 0.81%-units (95% CI 0.66–0.96) per allele in hemizygous men, and 0.68%-units (95% CI 0.38–0.97) in homozygous women. The G6PD variant may cause approximately 2% (N = 0.65 million, 95% CI 0.55–0.74) of African American adults with T2D to remain undiagnosed when screened with HbA1c. Limitations include the smaller sample sizes for non-European ancestries and the inability to classify approximately one-third of the variants. Further studies in large multiethnic cohorts with HbA1c, glycemic, and erythrocytic traits are required to better determine the biological action of the unclassified variants. As G6PD deficiency can be clinically silent until illness strikes, we recommend investigation of the possible benefits of screening for the G6PD genotype along with using HbA1c to diagnose T2D in populations of African ancestry or groups where G6PD deficiency is common. Screening with direct glucose measurements, or genetically-informed HbA1c diagnostic thresholds in people with G6PD deficiency, may be required to avoid missed or delayed diagnoses.

1 November 2003 in Journal of Molecular Biology
Verified
Journal Article
Closed access
TWThomas Weidemann
Thomas Weidemann
MWMalte Wachsmuth
Malte Wachsmuth
TKTobias Aurelius Knoch
Tobias Aurelius Knoch
GMGabriele Müller
Gabriele Müller
WWWaldemar Waldeck
Waldemar Waldeck
JLJörg Langowski
Jörg Langowski

12 October 2015 in Journal of Medical Internet Research
Verified
Journal Article
Open access
ARAlison Rowsell
Alison Rowsell
IMIngrid Muller
Ingrid Muller
EMElizabeth Murray
Elizabeth Murray
Paul LittlePaul Little
Paul Little
CBChris Byrne
Chris Byrne
LYLucy Yardley
Lucy Yardley
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet

23 January 2017 in Journal of Medical Internet Research
Verified
Journal Article
Open access
IMIngrid Muller
Ingrid Muller
ARAlison Rowsell
Alison Rowsell
BSBeth Stuart
Beth Stuart
VHVictoria Hayter
Victoria Hayter
Paul LittlePaul Little
Paul Little
LYLucy Yardley
Lucy Yardley
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet

25 April 2023 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
CGCorinna Grasemann
Corinna Grasemann
JHJakob Höppner
Jakob Höppner
PBPeter Burgard
Peter Burgard
MSMichael Schündeln
Michael Schündeln
NMNora Matar
Nora Matar
DCDaniela Choukair
Daniela Choukair
Purpose: The transition process from paediatric/adolescent to adult medical care settings is of utmost importance for the future health of adolescents with chronic diseases and poses even more difficulties in the context of rare diseases (RDs). Paediatric care teams are challenged to deliver adolescent-appropriate information and structures. Here we present a structured transition pathway which is patient-focused and adoptable for different RDs. Methods: The transition pathway for adolescents 16 years and older was developed and implemented as part of a multi-centre study in 10 university hospitals in Germany. Key elements of the pathway included: assessment of patients’ disease-related knowledge and needs, training/educational and counselling sessions, a structured epicrisis and a transfer appointment jointly with the paediatric and adult specialist. Specific care coordinators from the participating university hospitals were in charge of organization and coordination of the transition process. Results: Of a total of 292 patients, 286 completed the pathway. Deficits in disease-specific knowledge were present in more than 90% of participants. A need for genetic or socio-legal counselling was indicated by > 60%. A mean of 2.1 training sessions per patient were provided over a period of almost 1 year, followed by the transfer to adult care in 267 cases. Twelve patients remained in paediatric care as no adult health care specialist could be identified. Targeted training and counselling resulted in improved disease-specific knowledge and contributed to empowering of patients. Conclusion: The described transition pathway succeeds to improve health literacy in adolescents with RDs and can be implemented by paediatric care teams in any RD specialty. Patient empowerment was mainly achieved by individualized training and counselling.

18 February 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JBJonas Bendig
Jonas Bendig
AWAnna-Sophie Wolf
Anna-Sophie Wolf
TMTony Mark
Tony Mark
AFAnika Frank
Anika Frank
JMJosephine Mathiebe
Josephine Mathiebe
Björn FalkenburgerBjörn Falkenburger
Björn Falkenburger
Symptoms of Parkinson’s disease (PD) can be controlled well, but treatment often requires expert judgment. Telemedicine and sensor-based assessments can allow physicians to better observe the evolvement of symptoms over time, in particular with motor fluctuations. In addition, they potentially allow less frequent visits to the expert’s office and facilitate care in rural areas. A variety of systems with different strengths and shortcomings has been investigated in recent years. We designed a multimodal telehealth intervention (TelePark) to mitigate the shortcomings of individual systems and assessed the feasibility of our approach in 12 patients with PD over 12 weeks in preparation for a larger randomized controlled trial. TelePark uses video visits, a smartphone app, a camera system, and wearable sensors. Structured training included setting up the equipment in patients’ homes and group-based online training. Usability was assessed by questionnaires and semi-standardized telephone interviews. Overall, 11 out of 12 patients completed the trial (5 female, 6 male). Mean age was 65 years, mean disease duration 7 years, mean MoCA score 27. Adherence was stable throughout the study and 79% for a short questionnaire administered every second day, 62% for medication confirmation, and 33% for an electronic Hauser diary. Quality of life did not change in the course of the study, and a larger cohort will be required to determine the effect on motor symptoms. Interviews with trial participants identified motivations to use such systems and areas for improvements. These insights can be helpful in designing similar trials.